

Summary of Presentation from the Targeted Therapy in Lung Cancer Meeting

Ramaswamy Govindan, MD

Abstract: New pathways are being identified now on a regular basis, and novel agents are being tested in a wide variety of clinical trials for patients with advanced non-small cell lung cancer. Excitement over progress in one area is tempered naturally by disappointing results in other areas. Each year, leading lung cancer experts meet in Santa Monica to discuss the progress in the field of molecularly targeted therapy in non-small cell lung cancer. Annual conferences similar to the one held in Santa Monica serve mainly as a catalyst to promote new ideas and foster active collaboration. We have invited participants to provide very brief succinct summaries of the presentations for this supplement. The articles in this supplement should be viewed more as meeting reports than as exhaustive and comprehensive review articles.

Key Words: Lung cancer, Molecularly targeted therapies.

(*J Thorac Oncol.* 2011;6: S1757–S1826)

Division of Oncology, Washington University School of Medicine, St. Louis, Missouri.

Disclosure: Ramaswamy Govindan, MD, has served as a consultant for BI, Genentech, Lilly, BMS, and Pfizer.

Address for correspondence: Ramaswamy Govindan, MD, Division of Oncology, Washington University School of Medicine, St. Louis, MO. E-mail: rgovinda@dom.wustl.edu

Copyright © 2011 by the International Association for the Study of Lung Cancer

ISSN: 1556-0864/11/0611-1757

Just like every year over the past decade, leading experts with special research interest in lung cancer from around the world met again a few months ago in Santa Monica, California, to discuss strategies for improving the outcomes of patients with lung cancer using molecularly targeted therapies. As has been made clear before, this is a large “work in progress” meeting. New pathways are being identified now on a regular basis, and novel agents are being tested in a wide variety of clinical trials for patients with advanced non-small cell lung cancer. Excitement over progress in one area is tempered naturally by disappointing results in other areas. Annual conferences similar to the one held in Santa Monica serve mainly as a catalyst to promote new ideas and foster active collaboration. Because the meeting is restricted to a few individuals, we feel that this supplement on presentations from the “Santa Monica Meeting” would be of great interest to the oncology community. As before, we asked our contributors to provide only very brief succinct summaries and limit references and figures to a bare minimum. The articles in this supplement should be viewed more as meeting reports than as exhaustive and comprehensive review articles. We hope you the readers of the *Journal of Thoracic Oncology* will find the supplement instructive and useful. I am grateful to the contributors for their help and to Drs. Paul Bunn, David Johnson, and Roy Herbst for conceiving and organizing this “Santa Monica Meeting” year after year.